1st Edition
SARS-CoV-2 Variants and Global Population Vulnerability Diagnostic Strategies, Vaccine Development, and Therapeutic Management
Foreword by Elrashdy M. Redwan
1. Zoonotic Origin, Genomic Organization, Transmission, and Mutation of SARS-CoV-2
Ashutosh Singh, Rehan Fazal, Upasana Sahu, Manoj Kumar, Sandeep Bhatia, Aniket Sanyal, and Naveen Kumar
2. SARS-CoV-2 Life Cycle and Immuno-Pathophysiology
Alberto Rubio-Casillas and Vladimir N. Uversky
3. Conventional and Novel Diagnostics for the Detection of SARS-CoV-2 Variants
Bruno Andrade, Robinson Sabino-Silva, and Aristóteles Góes-Neto
4. Biosensors: An Advanced and Sensitive Analytical Technique for the Early Detection of SARS-CoV-2 Variants
Siva Nageswararao Gajula, Lakshmi Vineela Nalla, and Vivek P Chavda
5. Global Impact of Delta and Omicron Variants of SARS-CoV-2
Lawandashisha Nongrang, Rajashri Bezbaruah, Tutumoni Kalita, Kangkan Deka, Bitu Gogoi, and Prativa Sadhu
6. Drug Repurposing for Covid-19 and Fast Track New Drug Discovery for Emerging SARS-CoV-2 Variants
Divya Teli, Amit Chaudhari, Disha Patel, and Mahesh Chhabria
7. Characterization of SARS-CoV-2 Variants Using Respiratory Organoids and Organs on a Chip (OOACs)
Yukio Watanabe and Kazuo Takayama
8. Fast-Track Vaccine Development for Covid-19 and Impact of Emerging Variants
Alaa A. A. Aljabali, Mohammad A. Obeid, and Murtaza M. Tambuwala
9. Nasal Vaccine for the Control of Emerging Variants of SARS-CoV-2
Anup Kumar, Dixa A. Vaghela, Pankti C. Balar, Kajal Bhavisker, Rajashri Bezbaruah, Lawandashisha Nongrang, Anjali P. Bedse, and Vivek P. Chavda
10. Role of Nucleic Acid Vaccines for the Management of Emerging Variants of SARS-CoV-2
Kenneth Lundstrom
11. Role of Monoclonal Antibodies for the Management of Immersing Variant of SARS-CoV-2
Vivek P. Chavda, Hetvi K. Solanki, Subhash C. Chauhan, and Murali M. Yallapu
12. Dietary Supplements and Nutraceuticals Against Variants of SARS-CoV-2
Amit Z. Chaudhari, Divya Teli, Pankti C. Balar, Jimil Gandhi, and Vivek P. Chavda
13. Herbal Remedies for Covid-19 Management
Hitesh Malhotra, Amrit Sarwara, Vandana Garg, Rohit Dutt, Vineet Mittal, and Rajeev K. Singla
14. Covid-19 and Post-Covid-19 Associated Complications and Their Management
Mit Joshi and Bhoomika M. Patel
15. SARS-CoV-2 Variants and Global Vulnerability: Diagnostic, Vaccines, and Therapeutic Management
Rasha M. Bashatwah, Alaa A. A. Aljabali, and Murtaza M. Tambuwala
16. Socio-Economic and Environmental Impact of SARS-CoV-2 Variants
Altijana Hromiæ-Jahjefendiæ, Vivek P. Chavda, and Lakshmi Vineela Nalla
17. Nanotechnology-Based Interventions for Covid-19 Management
Vivek P. Chavda, Akta Vaishnav, Kavindra Kumar Kesariand, and Bruce D. Uhal
18. SARS-CoV-2 Variants and Covid-19 Pandemic: Future Perspectives
Vivek P. Chavda and Vladimir N. Uversky
Biography
Vivek P. Chavda, MPharm, is currently working as an Assistant Professor in the Department of Pharmaceutics and Pharmaceutical Technology at the L. M. College of Pharmacy, Ahmedabad, Gujarat, India. Before joining academia, he served in the biologics industry for almost eight years in research and development with two successful regulatory filings at Lupin Biotech (Pune) and Dr. Reddy‘s Laboratory (Hyderabad). He has more than 150 national and international publications, nearly 20 book chapters, several books, one patent in progress as well as numerous newsletter articles to his credit. His research interests include development of biologics processes and formulations, medical device development, nano-diagnostics, long-acting parenteral formulations, and nano-vaccines. He earned his BPharm and MPharm degrees (with gold medals) at Gujarat Technological University, Gujarat, India.
Vladimir N. Uversky, PhD, DSc, FRSB, FRSC, is a full Professor in the Department of Molecular Biology, University of South Florida, Tampa, Florida, USA. Dr. Uversky works on various aspects of protein intrinsic disorder phenomenon and on analysis of protein folding and misfolding. He has authored over 1150 scientific publications. According to the Thomson Reuters’ Web of Science, his work was cited over 66,000 times, and he has an h-index of 126. Dr. Uversky has been included in the prestigious Clarivate List of Highly Cited Researchers™ every year from 2014 to 2020. In 2021, he was elected as a Fellow of the Royal Society of Biology and a Fellow of the Royal Society of Chemistry. Over the years, he has delivered more than 240 invited talks at various national and international conferences and invited seminars in various universities and research institutions around the globe. Dr. Uversky has collaborated with more than 12,500 colleagues from more than 2,750 research organizations in 89 countries/territories. He is an editor of a number of scientific journals and has edited several books and book series on protein structure, function, folding, and misfolding. He obtained his PhD in Biophysics from the Moscow Institute of Physics and Technology and DSc in Biophysics from the Institute of Experimental and Theoretical Biophysics, Russian Academy of Sciences.
"Well-written chapters containing detailed information . . . The multi-author approach resulted in a uniquely prepared book on the global vulnerability of SARS-CoV-2, which is hoped to be of interest to researchers in this field. . . . Novel diagnostic techniques and biosensors are introduced with figures and schematics for better understanding. This book also focuses on global data on virus and vaccine development. Since in the pandemic, people also use herbal remedies to prevent symptoms, this book contains information on such herbal remedies. The last part of the book discusses the social and environmental impacts of COVID-19 and considers future aspects for the betterment of mankind."
—From Foreword by Prof. Elrashdy M. Redwan, Department of Biological Science, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia
